ERBB2 and breast cancer: Next, ASSIGN was used to estimate the activation of each GFRN member (AKT, BAD, EGFR, HER2, IGF1R, KRAS (G12V), and RAF1) in 1119 breast cancer patient samples from TCGA and 55 samples from the ICBP panel of breast cancer cell lines.